| McAfee, Inc. Offers First Virtual Trial of Security Appliance
SANTA CLARA, Calif., Oct. 23 /PRNewswire-FirstCall/ -- McAfee, Inc. (NYSE: MFE) today announced a virtual machine trial of the McAfee Secure Internet Gateway appliance. The free 30-day software trial is designed to help mid-sized businesses evaluate McAfee Secure Internet Gateway, an integrated Web and e-mail security appliance that helps businesses defend their networks from spam, viruses, spyware and malicious Web sites. "For the first time, customers can try a spam-filtering appliance through the download of a virtual software file, to see how it performs relative to their current anti-spam solution," said Jack Marsal, director of product marketing for McAfee. "We're giving customers the opportunity to experience the benefits of McAfee Secure Internet Gateway on their own server, before making an investment in an appliance." The VMware trial has the same features and effectiveness of the physical Secure Internet Gateway appliance.
Winmail Mail Server 4.5 build 0912
Winmail Server is an enterprise class mail server software system offering a robust feature set, including extensive security measures. Winmail Server supports SMTP, POP3, IMAP, Webmail, LDAP, multiple domains, SMTP authentication, spam protection, anti-virus protection, SSL/TLS security, Network Storage, remote access, Web-based administration, and a wide array of standard email options such as filtering, signatures, real-time monitoring. Version 4.5 build 0912 includes international support enhancements. CNET Networks is not responsible for the content of this Publisher's Description. We encourage you to determine whether this product or your intended use is legal. We do not encourage or condone the use of any software in violation of applicable laws. Any questions, complaints or claims related to any specific download should be directed to the relevant vendor.
Snorting a Brain Chemical Could Replace Sleep
In what sounds like a dream for millions of tired coffee drinkers, Darpa-funded scientists might have found a drug that will eliminate sleepiness. A nasal spray containing a naturally occurring brain hormone called orexin A reversed the effects of sleep deprivation in monkeys, allowing them to perform like well-rested monkeys on cognitive tests. The discovery's first application will probably be in treatment of the severe sleep disorder narcolepsy. The treatment is "a totally new route for increasing arousal, and the new study shows it to be relatively benign," said Jerome Siegel, a professor of psychiatry at UCLA and a co-author of the paper. "It reduces sleepiness without causing edginess." Orexin A is a promising candidate to become a "sleep replacement" drug.
|
